Coming Soon from Emmaus Medical, Inc.

Endari

Introducing the first and only approved treatment for
sickle cell disease in pediatric patients 5 years and older and
the first in nearly 20 years for adults.

Contact for more information:

INDICATION

Endari™ is indicated to reduce the acute complications
of sickle cell disease in adult and pediatric patients 5 years and older.

Copyright 2018 Emmaus Medical, Inc. All rights reserved.
Endari™ is registered trademark of Emmaus Medical, Inc.

INDICATION

Endari™ [L-glutamine oral powder] is an FDA-approved prescription drug indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

IMPORTANT SAFETY INFORMATION

Endari’s safety profile was similar to placebo and well-tolerated in pediatric and adult patients. The most common adverse reactions occurring in greater than 10 percent of patients treated with Endari were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain (non-cardiac).

Endari should only be taken under the direction of a physician. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.

The information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries. Use and access of this site is subject to the terms and conditions as set out in our Terms of Use and Internet Privacy Policy.

For additional information about Endari, please read the Endari Full Prescribing Information and talk to your doctor. You can also call 1-877-420-6493. Endari is available by prescription only.

You may report side effects to FDA at 1-800-FDA-1088.